

# Saxenda® Dosing Guide

## Initiating treatment with Saxenda® for chronic weight management in adults

Saxenda® (liraglutide injection) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:<sup>1</sup>


- 30 kg/m<sup>2</sup> or greater (obesity), or
- 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.



## Simple, once-daily dosing at any time of day, independent of meals<sup>1</sup>

Patients should follow a progressive dose escalation to achieve the maintenance dose of 3.0 mg/day

The dose escalation schedule should be used to reduce the likelihood of gastrointestinal symptoms.



- If patients do not tolerate an increased dose during dose escalation, each step in the dose escalation can be delayed up to 7 days
- If a patient has not lost at least 5% of their initial body weight after 12 weeks on the 3.0-mg maintenance dose, treatment with Saxenda® should be discontinued

Please see the Product Monograph for the complete dosing and administration information.

Demonstrate the first injection in the office to help patients get started

1 attach needle



2 select dose



3 inject dose



4 remove needle



A prescription is only required for needles if your patient has private insurance that provides coverage for them.



Scan this QR code with your smartphone camera to visit [SaxendaHCP.ca](https://www.saxenda.com/healthcare-professionals) and find out more about Saxenda®



**Encourage your patients to enrol in the**  
**SaxendaCare® Patient Support Program by visiting [Saxenda.ca](https://www.saxenda.com)\* today!**

Consult the Product Monograph at <https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/saxenda-product-monograph.pdf> for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.

\*Saxenda.ca also contains content for the general public.

**Reference:**

1. Saxenda® Product Monograph. Novo Nordisk Canada Inc. December 9, 2022.



Saxenda® and SaxendaCare® are registered trademarks of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc. **Novo Nordisk Canada Inc.**, Tel: (905) 629-4222 or 1-800-465-4334. [www.novonordisk.ca](http://www.novonordisk.ca)  
© Novo Nordisk Canada Inc.

CA235X00002E

